Business
Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries today announced a collaboration with the pioneering research group of Dr. Mark Adams, a leading cancer genomics expert in the School of Biomedical Sciences and Faculty of Health at the Queensland University of Technology (QUT), Australia. This partnership aims to accelerate the discovery and optimization
About this update from Evogene Ltd.
[{"type":"text","content":"Aiming to introduce a new therapeutic strategy for overcoming chemotherapy resistance in lung cancer due to increased expression of cellular pathways","length":149,"tagName":"p","attribs":{}},{"type":"text","content":"REHOVOT, Israel, Feb. 17, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries today announced a collaboration with the pioneering research group of Dr. Mark Adams, a leading cancer genomics expert in the School of Biomedical Sciences and Faculty of Health at the Queensland University of Technology (QUT), Australia. This partnership aims to accelerate the discovery and optimization of novel small molecules as potential drug candidates for the treatment of chemotherapy and targeted therapy-resistant non-small cell lung cancer (NSCLC), as well as other cancers.","length":733,"tagName":"p"},{"type":"image","alt":"Evogene Logo","displaySize":"","headline":null,"caption":"Evogene Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":133,"url":"https://media.zenfs.com/en/prnewswire.com/87509d2ca5cc8d14fc76fdea74d5c6d4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OILrGqyrDS.vtXz6ah5zmA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIzNDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/87509d2ca5cc8d14fc76fdea74d5c6d4","width":400,"height":133}}},{"type":"text","content":"Despite significant advancements in cancer treatment, resistance to standard-of-care chemotherapies and targeted therapies remain a major hurdle in treating patients with aggressive cancers, such as NSCLC. The effectiveness of cornerstone therapies such as Cisplatin is limited by high intrinsic resistance, seen in 60-70% of treated patients1, while 30-40% of patients receiving targeted therapies also fail to respond upfront2. In immunotherapy, whether as monotherapy or combined with chemotherapy, similar rates of both intrinsic and acquired resistance are observed3. These patterns highlight an urgent need for more effective therapies that can overcome both intrinsic and acquired treatment resistance.","length":714,"tagName":"p"},{"type":"text","content":"Based on breakthrough findings from Dr. Adams' lab uncovering a novel druggable cellular det...